Package | us.nlm.vsac |
Type | ValueSet |
Id | 2.16.840.1.113762.1.4.1078.678 |
FHIR Version | R4 |
Source | http://fhir.org/packages/us.nlm.vsac/https://vsac.nlm.nih.gov/valueset/2.16.840.1.113762.1.4.1078.678/expansion |
URL | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.678 |
Version | 20231006 |
Status | active |
Date | 2023-10-06T01:03:19-04:00 |
Name | SGLT2iDMCKD |
Title | SGLT2i DM CKD |
Realm | us |
Authority | hl7 |
Purpose | (Clinical Focus: Medications containing SLGT2 inhibitors that have evidence for benefit in CKD per the ADA Standards of Care in Diabetes 2023),(Data Element Scope: DRUG_CLASS_MEMBERS: PHARMACOLOGIC:),(Inclusion Criteria: RxCUIs for medications containing one of the following: * Canagliflozin * Dapagliflozin * Empagliflozin),(Exclusion Criteria: None) |
No resources found
CodeSystem | |
rxnorm | RxNorm |
rxnorm | RxNorm |
No narrative content found in resource